Xuantai Pharmaceutical (688247.SH) released its performance for the first three quarters, with net profit attributable to the parent company of 34.08 million yuan, a year-on-year decrease of 46.30%.

Zhitong Finance APP News, Xuantai Pharmaceutical (688247.SH) disclosed its 2026 third-quarter report. In the first three quarters, the company achieved operating revenue of 283 million yuan, a year-on-year decrease of 14.75%; net profit attributable to the parent company was 34.08 million yuan, a year-on-year decrease of 46.30%; net profit after deducting non-recurring gains and losses was 24.74 million yuan, a year-on-year decrease of 54.08%; basic earnings per share were 0.08 yuan.